Popular search terms:
Search Results
89 results found-
January is National Mentoring Month, but some seek STEM-focused learning year-round.
https://www.cslbehring.ca/news/2018/20180130-mentoring-month -
Dr. Andrea Douglas of CSL Behring discusses bringing women into STEM fields and raising them to the executive ranks.
https://www.cslbehring.ca/news/2018/20180124-women-in-stem -
Welcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
https://www.cslbehring.ca/news/2019/38th-annual-john-molson -
Our vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.
https://www.cslbehring.ca/our-company/sustainability -
The Global Leadership Group at CSL believes in creating an environment that fosters innovation and strives to meet the needs of patients.
https://www.cslbehring.ca/our-company/global-leadership-group -
Welcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
https://www.cslbehring.ca/accessibility-statement -
Here you can find an overview of all the products that we offer in Canada.
https://www.cslbehring.ca/products/product-list -
Welcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
https://www.cslbehring.ca/terms-of-use -
Welcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
https://www.cslbehring.ca/news/2025/health-canada-has-authorized-csl-andembry